The ASCO Annual Meeting is where many new cancer research findings are announced. Today’s key research highlights include an effective medication for metastatic prostate cancer, targeted therapy that slows the growth of metastatic pancreatic cancer, how socioeconomic factors may affect survival for multiple myeloma, and how the ACA resulted in earlier treatment and improved equality in care.

The 2019 Genitourinary Cancers Symposium will feature new research on treatments for prostate cancer and kidney cancer.

Exercise can greatly improve the physical and mental health of men with prostate cancer. Exercise specialist Carol Michaels shares what the benefits are and how to start a program that’s right for you.

In this podcast, Dr. Brian Rini and Dr. Jorge Garcia discuss the latest research in genitourinary cancers presented at the 2018 ESMO Congress.

Oncology professionals from around the globe are at the 2018 ASCO Annual Meeting. Today’s key research highlights include the effects of geriatric assessment on patient-doctor communication, treatments for advanced prostate cancer that may work better in black men, the possibility that women are undertreated for head and neck cancer, and a comparison of treatment costs for colorectal cancer between the U.S. and Canada.

The 2018 Genitourinary Cancers Symposium includes exciting research that focuses on effective treatment options for kidney cancer, prostate cancer, and bladder cancer.

After androgen-deprivation therapy for prostate cancer, many couples are surprised by the physical and emotional changes that come into their relationship because of a lack of testosterone.

Survivor and patient advocate Robert Harrison discusses how his metastatic prostate cancer is just one part of his life’s journey.

Listen to some of the most exciting research news from the 2017 ASCO Annual Meeting in this Research Round Up podcast.

Oncology professionals from around the globe are in Chicago for the ASCO Annual Meeting. Research highlights from today include pregnancy after breast cancer, abiraterone for prostate cancer, a new medication that targets a rare genetic abnormality, new blood test technology for cancer screening, and genomic testing.